MA35061B1 - Dérivés de pyrazolospirocétone pour une utilisation comme inhibiteurs d'acétyl-coa carboxylase - Google Patents

Dérivés de pyrazolospirocétone pour une utilisation comme inhibiteurs d'acétyl-coa carboxylase

Info

Publication number
MA35061B1
MA35061B1 MA36357A MA36357A MA35061B1 MA 35061 B1 MA35061 B1 MA 35061B1 MA 36357 A MA36357 A MA 36357A MA 36357 A MA36357 A MA 36357A MA 35061 B1 MA35061 B1 MA 35061B1
Authority
MA
Morocco
Prior art keywords
acetyl
coa carboxylase
pyrazolospirocetone
derivatives
carboxylase inhibitors
Prior art date
Application number
MA36357A
Other languages
English (en)
Inventor
David Andrew Griffith
Robert Lee Dow
James Alfred Southers Jr
David James Edmonds
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA35061B1 publication Critical patent/MA35061B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Photographic Processing Devices Using Wet Methods (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

L'INVENTION PORTE SUR UN COMPOSÉ DE FORMULE (I) OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, DANS LAQUELLE FORMULE G REPRÉSENTE (II) OU (III) ET R1, R2 ET R3 SONT TELS QUE DÉCRITS DANS LA DESCRIPTION ; SUR DES COMPOSITIONS PHARMACEUTIQUES DE CELUI-CI ; ET SUR LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES, D'AFFECTIONS OU DE TROUBLES MODULÉS PAR L'INHIBITION D'UNE OU PLUSIEURS ENZYMES ACÉTYL-COA CARBOXYLASES CHEZ UN ANIMAL.
MA36357A 2011-04-22 2012-04-09 Dérivés de pyrazolospirocétone pour une utilisation comme inhibiteurs d'acétyl-coa carboxylase MA35061B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161478240P 2011-04-22 2011-04-22
PCT/IB2012/051732 WO2012143813A1 (fr) 2011-04-22 2012-04-09 Dérivés de pyrazolospirocétone destinés à être utilisés comme inhibiteurs d'acétyl-coa carboxylase

Publications (1)

Publication Number Publication Date
MA35061B1 true MA35061B1 (fr) 2014-04-03

Family

ID=46025823

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36357A MA35061B1 (fr) 2011-04-22 2012-04-09 Dérivés de pyrazolospirocétone pour une utilisation comme inhibiteurs d'acétyl-coa carboxylase

Country Status (41)

Country Link
US (4) US8802688B2 (fr)
EP (1) EP2699576B1 (fr)
JP (1) JP5657174B2 (fr)
KR (1) KR101567659B1 (fr)
CN (2) CN103492388A (fr)
AP (1) AP3499A (fr)
AR (1) AR086198A1 (fr)
AU (1) AU2012245996B2 (fr)
CA (1) CA2831380C (fr)
CL (1) CL2013002794A1 (fr)
CO (1) CO6801757A2 (fr)
CR (1) CR20130464A (fr)
CU (1) CU24164B1 (fr)
CY (1) CY1117122T1 (fr)
DK (1) DK2699576T3 (fr)
DO (1) DOP2013000243A (fr)
EA (1) EA022375B1 (fr)
EC (1) ECSP13013038A (fr)
ES (1) ES2561452T3 (fr)
GE (1) GEP20166474B (fr)
GT (1) GT201300258A (fr)
HR (1) HRP20151397T1 (fr)
HU (1) HUE028602T2 (fr)
IL (1) IL228949A (fr)
MA (1) MA35061B1 (fr)
ME (1) ME02312B (fr)
MX (1) MX348860B (fr)
MY (1) MY162167A (fr)
NI (1) NI201300111A (fr)
NZ (1) NZ616156A (fr)
PE (1) PE20141187A1 (fr)
PL (1) PL2699576T3 (fr)
PT (1) PT2699576E (fr)
RS (1) RS54526B1 (fr)
SG (1) SG194142A1 (fr)
SI (1) SI2699576T1 (fr)
TN (1) TN2013000393A1 (fr)
TW (1) TWI464171B (fr)
UA (1) UA107753C2 (fr)
UY (1) UY34027A (fr)
WO (1) WO2012143813A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102695708B (zh) * 2009-11-10 2014-10-15 辉瑞大药厂 N1-吡唑并螺酮乙酰辅酶a羧化酶抑制剂
CN102491974B (zh) 2011-12-12 2013-08-07 南京药石药物研发有限公司 1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法
US9447025B2 (en) 2013-03-14 2016-09-20 Kalyra Pharmaceuticals, Inc. Bicyclic analgesic compounds
US10208044B2 (en) 2013-05-10 2019-02-19 Gilead Apollo, Llc ACC inhibitors and uses thereof
BR112015028152A2 (pt) 2013-05-10 2017-07-25 Nimbus Apollo Inc inibidores de acc e usos dos mesmos
US9988399B2 (en) * 2013-05-10 2018-06-05 Gilead Apollo, Llc Bicyclic compounds as ACC inhibitors and uses thereof
WO2015036892A1 (fr) * 2013-09-12 2015-03-19 Pfizer Inc. Utilisation d'inhibiteurs de l'acétyl-coa carboxylase pour traiter l'acné vulgaire
JPWO2015056782A1 (ja) 2013-10-17 2017-03-09 塩野義製薬株式会社 新規アルキレン誘導体
CN105814013A (zh) 2013-12-12 2016-07-27 卡利拉制药公司 双环烷基化合物及合成
JP6741343B2 (ja) * 2014-03-07 2020-08-19 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー プロペラン誘導体および合成
CA2892342C (fr) 2014-05-22 2016-11-01 Sylvain-Paul Morency Outil et methode de depalletisation de couche
JP6833677B2 (ja) 2014-09-17 2021-02-24 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー 二環式化合物
WO2017114413A1 (fr) * 2015-12-31 2017-07-06 江苏天士力帝益药业有限公司 Triacétyl-3-hydroxyphényladénosine et application dans la préparation de médicament pharmaceutique permettant de prévenir ou traiter la stéatose hépatique non alcoolique
CN106580986B (zh) * 2016-11-28 2017-09-15 王保亮 一种治疗少弱精子症的药物组合物
CA3063729A1 (fr) 2017-05-15 2018-11-22 Recurium Ip Holdings, Llc Composes analgesiques
HUE061885T2 (hu) * 2017-11-21 2023-08-28 Pfizer 4-(4-(4-(1-Izopropil-7-oxo-1,4,6,6,7-tetrahidrospiro[indazol-5,4'-piperidin] -1'-karbonil)-6-metoxipiridin-2-il)-benzoesav kristályos 2-amino-2-(hidroximetil)-propán-1,3-diol sója
CN111574530B (zh) * 2020-04-21 2022-07-26 徐州医科大学 一种acc抑制剂及其医药用途
CN118271307A (zh) * 2022-12-30 2024-07-02 苏州浦合医药科技有限公司 Prmt5-mta抑制剂

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0901786T3 (da) 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
KR20030076716A (ko) 2001-02-28 2003-09-26 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 효능제로서 아실화 피페리딘 유도체
EP1478437B1 (fr) 2002-02-27 2005-08-31 Pfizer Products Inc. Inhibiteurs de l'acetyl-coa-carboxylase
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
WO2004092179A1 (fr) 2003-04-14 2004-10-28 Nippon Soda Co. Ltd. Derive spiro, procede de production et antioxydant
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
PL1753748T3 (pl) 2004-05-12 2010-01-29 Pfizer Prod Inc Pochodne proliny i ich zastosowanie jako inhibitorów peptydazy dipeptylowej IV
WO2005113069A2 (fr) 2004-05-14 2005-12-01 Research Development Foundation Utilisation de curcumine et d'analogues de curcumine comme inhibiteurs de l'acc2
EA010888B1 (ru) 2004-05-25 2008-12-30 Пфайзер Продактс, Инк. Тетраазабензо[е]азуленовые производные и их аналоги
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
JP5076159B2 (ja) 2005-07-19 2012-11-21 メルク・シャープ・エンド・ドーム・コーポレイション アセチルコエンザイムａカルボキシラーゼ（ａｃｃ）阻害薬としてのスピロクロマノン誘導体
US20100160255A1 (en) 2005-07-29 2010-06-24 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
AU2006316626A1 (en) 2005-11-18 2007-05-31 Merck Sharp & Dohme Corp. Spirohydantoin aryl CGRP receptor antagonists
CA2641766A1 (fr) 2006-02-15 2007-08-23 Abbott Laboratories Nouveaux inhibiteurs d'acetyl-coa carboxylase (acc) et leur utilisation dans le traitement du diabete, de l'obesite et du syndrome metabolique
ES2487967T3 (es) 2006-04-20 2014-08-25 Pfizer Products Inc. Compuestos amido heterocíclicos condensados con fenilo para la prevención y el tratamiento de enfermedades mediadas por la glucoquinasa
AP2009004880A0 (en) 2006-11-29 2009-06-30 Pfizer Prod Inc Spiroketone acetyl-COA carboxylase inhibitors
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
WO2008102749A1 (fr) * 2007-02-20 2008-08-28 Takeda Pharmaceutical Company Limited Composé hétérocyclique
KR101113387B1 (ko) 2007-04-12 2012-04-23 화이자 인코포레이티드 단백질 키나아제 ｃ의 억제제로서의 3-아미도-피롤로［3,4-ｃ］피라졸-5(1ｈ,4ｈ,6ｈ)카브알데하이드 유도체
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
JP2011521940A (ja) 2008-05-28 2011-07-28 ファイザー・インク ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤
ES2545231T3 (es) 2008-05-28 2015-09-09 Pfizer Inc. Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa
US8524730B2 (en) * 2008-07-04 2013-09-03 Msd K.K. Spirochromanone carboxylic acids
CA2730493A1 (fr) 2008-07-14 2010-01-21 Cropsolution, Inc. Modulateurs de l'acetyl-coenzyme a carboxylase et procedes d'utilisation associes
WO2010013161A1 (fr) 2008-07-29 2010-02-04 Pfizer Inc. Hétéroaryles fluorés
RS52236B (en) 2008-08-28 2012-10-31 Pfizer Inc. DIOKASA-BICYCLE DERIVATIVES (3.2.1) OCTOBER-2,3,4-TRIOLA
WO2010086820A1 (fr) 2009-02-02 2010-08-05 Pfizer Inc. Dérivés de 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazépin-6(5h)-yl)phényle
CA2754681C (fr) 2009-03-11 2014-01-07 Pfizer Inc. Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
US20110319379A1 (en) 2009-03-11 2011-12-29 Corbett Jeffrey W Substituted Indazole Amides And Their Use As Glucokinase Activators
EP2408780A2 (fr) 2009-03-20 2012-01-25 Pfizer Inc. 3-oxa-7-azabicycloý3,3.1¨nonanes
JP2012526096A (ja) 2009-05-08 2012-10-25 ファイザー・インク Ｇｐｒ１１９調節因子
WO2010128425A1 (fr) 2009-05-08 2010-11-11 Pfizer Inc. Modulateurs de gpr119
AU2010255422B2 (en) 2009-06-05 2014-04-10 Pfizer Inc. 1- ( piperidin-4-yl) -pyrazole derivatives as GPR 119 modulators
WO2011005611A1 (fr) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Agonistes du récepteur de la neuromédine u et leurs utilisations
CN102695708B (zh) * 2009-11-10 2014-10-15 辉瑞大药厂 N1-吡唑并螺酮乙酰辅酶a羧化酶抑制剂
EP2499140A1 (fr) * 2009-11-10 2012-09-19 Pfizer Inc. Inhibiteurs de n2-pyrazolospirocétone acétyl-coa carboxylase
US8859577B2 (en) * 2010-09-30 2014-10-14 Pfizer Inc. N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors

Also Published As

Publication number Publication date
CA2831380A1 (fr) 2012-10-26
UY34027A (es) 2013-04-05
EP2699576A1 (fr) 2014-02-26
RS54526B1 (en) 2016-06-30
PT2699576E (pt) 2016-03-09
US20150112068A1 (en) 2015-04-23
UA107753C2 (xx) 2015-02-10
US20120270893A1 (en) 2012-10-25
CN103492388A (zh) 2014-01-01
AR086198A1 (es) 2013-11-27
EP2699576B1 (fr) 2015-12-09
ECSP13013038A (es) 2014-01-31
SG194142A1 (en) 2013-11-29
EA201391288A1 (ru) 2014-04-30
IL228949A (en) 2016-11-30
GT201300258A (es) 2015-06-02
CO6801757A2 (es) 2013-11-29
HUE028602T2 (hu) 2016-12-28
CR20130464A (es) 2013-10-16
NZ616156A (en) 2014-08-29
TW201305162A (zh) 2013-02-01
HRP20151397T1 (hr) 2016-01-15
GEP20166474B (en) 2016-05-10
JP5657174B2 (ja) 2015-01-21
KR101567659B1 (ko) 2015-11-09
MX2013012313A (es) 2014-01-31
AU2012245996A1 (en) 2013-10-03
AP2013007129A0 (en) 2013-09-30
PE20141187A1 (es) 2014-09-18
ES2561452T3 (es) 2016-02-26
CN106117205B (zh) 2018-09-21
CU20130126A7 (es) 2014-01-29
CA2831380C (fr) 2016-04-05
DOP2013000243A (es) 2013-12-31
PL2699576T3 (pl) 2016-05-31
US8802688B2 (en) 2014-08-12
CY1117122T1 (el) 2017-04-05
CU24164B1 (es) 2016-03-31
KR20140015511A (ko) 2014-02-06
CL2013002794A1 (es) 2013-12-27
MX348860B (es) 2017-06-30
EA022375B1 (ru) 2015-12-30
IL228949A0 (en) 2013-12-31
TN2013000393A1 (fr) 2015-01-20
US20150336958A1 (en) 2015-11-26
ME02312B (me) 2016-06-20
TWI464171B (zh) 2014-12-11
DK2699576T3 (en) 2016-02-15
CN106117205A (zh) 2016-11-16
WO2012143813A1 (fr) 2012-10-26
JP2014515755A (ja) 2014-07-03
NI201300111A (es) 2014-02-12
US20140323730A1 (en) 2014-10-30
SI2699576T1 (sl) 2016-02-29
AP3499A (en) 2015-12-31
AU2012245996B2 (en) 2016-09-01
MY162167A (en) 2017-05-31

Similar Documents

Publication Publication Date Title
MA35061B1 (fr) Dérivés de pyrazolospirocétone pour une utilisation comme inhibiteurs d'acétyl-coa carboxylase
MA33734B1 (fr) N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase
MA42295B1 (fr) Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation
MA38461A1 (fr) Inhibiteurs de la voie de la kynurénine
MA33636B1 (fr) Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine
MA34207B1 (fr) Inhibiteurs de la pi3 kinase et/ou du mtor
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
MA31873B1 (fr) Inhibiteurs de la peptide déformylase
MX2013004733A (es) Inhibidores de n1/n2-lactama acetil-coa carboxilasa.
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
EA200801826A1 (ru) Дейтерированные производные катехоламина и лекарственные средства, содержащие указанные соединения
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA37891B1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
MA32468B1 (fr) Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
MA38333A1 (fr) Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections
MA37691B1 (fr) 5-amino[1,4]thiazines comme inhibiteurs de bace1
MA49127B1 (fr) Dérivés d'indole n-substitués
MA46229A (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA37763A1 (fr) Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1
MA46342B1 (fr) Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation
MA33760B1 (fr) Dérivés spirolactames et leurs utilisations